In summary, our study verified that TAF15 and LINC00665 are downregulated in glioma tissues and cells, whereas MTF1, YY2, and GTSE1 are upregulated. Overexpression of TAF15 stabilized LINC00665, thus increasing its expression level to reduce the STAU1-mediated mRNA degradation of both MTF1 and YY2, further restraining the transcription of GTSE1, and ultimately disrupting the malignant progression of glioma. Moreover, we found that TAF15 overexpression, LINC00665 overexpression, MTF1(YY2) inhibition, and the combination of these three conditions all significantly reduced xenograft tumor growth in nude mice and prolonged their survival, with the combination group producing the smallest tumor size and longest survival. These results highlight the potential clinical application values of TAF15, LINC00665, MTF1, and YY2 respectively and cooperatively, which can provide novel strategies for molecular therapies for glioma.
